为什么法国医疗健康交易需要监管和渠道一起看？
法国医疗技术、诊断、医疗软件和专科服务企业可能具备研发、临床证据和欧洲渠道。中国买方可通过收购获得产品和市场入口。
但产品能否持续合规销售，以及渠道是否真正可控，是估值关键。
估值重点
买方应关注监管状态、临床证据、毛利率、渠道质量、知识产权、研发管线、客户集中和团队留任。
尽职调查重点
尽调应覆盖监管文件、临床资料、质量体系、经销商合同、产品责任、数据隐私、知识产权、税务和员工。
Lyndon如何协助
Lyndon可协助中国买方、法国医疗健康企业和顾问准备估值、资料室、监管风险清单和交易执行。
About the Author
Daniel Bae
Co-founder & CEO, Lyndon Advisory
Daniel is an investment banker with 15+ years of experience in M&A, having advised on deals worth over US$30 billion. His career spans Citi, Moelis, Nomura, and ANZ across London, Hong Kong, and Sydney. He holds a combined Commerce/Law degree from the University of New South Wales. Daniel founded Lyndon Advisory to solve the pain points in M&A, enabling bankers to focus on what matters most — delivering trusted advice to clients.
About Lyndon Advisory
Lyndon Advisory is an M&A advisory firm built for Asia Pacific. We help business owners sell their companies and investors make strategic acquisitions with senior-led execution, disciplined process management, and AI-supported buyer intelligence.
Learn about selling your business